Bynum L J, Parkey R W, Wilson J E
Arch Intern Med. 1977 Oct;137(10):1385-9.
Fibrinogen/fibrin degradation products (FDP/fdp) and soluble fibrin complexes (SFC) were measured serially in 60 patients heparinized for pulmonary embolism or deep venous thrombosis. Eight patients had recurrent thromboembolism. In patients without recurrence, FDP/fdp and SFC tended to normalize within three to five days. In patients with recurrence, results of both tests were significantly higher on admission, and FDP/fdp values were significantly higher throughout ten days of therapy, than in patients without recurrence. The SFC values were not different between the two groups during the first six days of treatment, but again became significantly higher on the seventh day in patients with recurrence. There were no differences in clotting times, heparin dosage, or any other clinical features between patients with and without recurrence. Measurement of FDP/fdp and SFC can help identify patients at risk of recurrent thromboembolism if performed serially during treatment.
对60例因肺栓塞或深静脉血栓形成而接受肝素治疗的患者,连续检测了纤维蛋白原/纤维蛋白降解产物(FDP/fdp)和可溶性纤维蛋白复合物(SFC)。8例患者发生了复发性血栓栓塞。在未复发的患者中,FDP/fdp和SFC往往在三至五天内恢复正常。在复发患者中,入院时两项检测结果均显著更高,且在整个十天的治疗过程中,FDP/fdp值均显著高于未复发患者。两组患者在治疗的前六天SFC值无差异,但复发患者在第七天再次显著升高。复发患者与未复发患者在凝血时间、肝素剂量或任何其他临床特征方面均无差异。如果在治疗期间连续进行检测,FDP/fdp和SFC的测定有助于识别有复发性血栓栓塞风险的患者。